Skip to main content
Toggle navigation
Search
Home
Back
Favorite
0
Like
Facebook
Print
Session IX: Hepatocellular Cancer
O-5: Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study
Thursday, June 30, 2022
15:30 – 15:42
Location: Auditorium A; Level 0
Abstract Presenter(s)
Arndt Vogel, MD
Medizinische Hochschule Hannover
Hannover, Germany
